berotralstat FDA approval date

The FDA approved berotralstat (Orladeyo) on 3 Dec 2020.

FDA approval date
3 Dec 2020

Drug identity checked against registry records

Also recorded as Orladeyo

Included trials

TrialSponsorPhaseStatusPrimary completion
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat StudiesNCT04933721BioCryst PharmaceuticalsPhase 3Enrolling by invitation2031-08Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2020-12-03DayberotralstatFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA214094", "applicant_as_listed_by_fda": "BIOCRYST", "brand_names": ["ORLADEYO"], "active_ingredients": ["BEROTRALSTAT DIHYDROCHLORIDE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20201203", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026